Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .

Essentiell

Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.
Statistik

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von externen Medienplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name YouTube
Zweck Zeige YouTube Inhalte
Name Twitter
Zweck Twitter Feeds aktivieren

Early HPV testing could detect sexually transmitted oral cancer

No. 34 | 18/06/2013

Antibodies to a high-risk type of human papillomavirus (HPV16) could help detect oropharyngeal(1) cancer several years before the clinical onset of the disease, reveals a new study from the International Agency for Research on Cancer (IARC) in cooperation with the German Cancer Research Center (DKFZ) and the United States National Cancer Institute (NCI) in an article published online today by the Journal of Clinical Oncology.

Computer-simulation of HPV
© dkfz.de

According to the results of the study, HPV16 E6 antibodies in the blood indicate a very high risk of developing an HPV-associated cancer of the oropharynx.

“These results are very encouraging. Up to now, it was not known whether these antibodies were present in blood before the cancer became clinically detectable. If these results are confirmed, future screening tools could be developed for early detection of the disease,” explained Dr Paul Brennan, Head of the Genetics Section at IARC and the senior author of the study. “To date there are no available markers for early detection of this cancer,” he said.

In the new study, of the 135 individuals who developed oropharyngeal cancer, 47 (about one third) had HPV16 E6 antibodies in their blood up to 12 years before the onset of disease, compared with only 9 of 1599 individuals who did not develop the cancer (less than 1%). All participants were part of the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which comprises more than 500 000 individuals from 10 European countries who were recruited in the 1990s and have been followed up since then.

Another significant finding of this landmark study was that patients with oropharyngeal cancer who had tested positive for antibodies against HPV16 E6 before cancer diagnosis were 3 times as likely to be alive 5 years after their diagnosis as those oropharyngeal cancer patients who had tested negative for these antibodies.

Although HPV is better known for causing cervical cancer and other genital cancers, it is also responsible for an increasing number of cancers of the oropharynx, particularly among men, and about 30% of oropharyngeal cancers worldwide are estimated to be HPV-related. The main type of HPV associated with these cancers is HPV16.

Oropharyngeal cancer has been a relatively uncommon cancer, traditionally associated with heavy tobacco smoking and heavy alcohol consumption. But over the past few decades its occurrence has increased dramatically in many parts of the world, especially in Europe and North America. This increase is thought to be due to the growing number of infections with HPV and to changing sexual practices, such as an increase in oral sex.

“These exciting findings are particularly important because of the worrying increase in the numbers of this type of cancer,” said Dr Christopher Wild, Director of IARC. “The work shows how innovative laboratory tests may help us develop tools to prevent or detect cancer early as well as improve treatment of the disease.”

(1) Oropharyngeal cancer includes cancers of the tonsils, the oropharynx (the oral part of the pharynx), the soft palate, and the base of the tongue.

Aimee R. Kreimer, Mattias Johansson, Tim Waterboer, et al. Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer, Journal of Clinical Oncology 2013, DOI: 10.1200/JCO.2012.47.2738

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS